← Leaderboards
David H Wagner
University Of Colorado Denver
$7,807,688
Attributed
$7,807,688
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,807,688 · 8
By mechanism
R42$3,340,969 · 2
R01$3,244,372 · 2
R41$808,197 · 3
R21$414,150 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Mayumi Fujita$5,471,263
- Sally P Stabler$1,782,834
- John C Hutton$5,451,482
- Robert W Schrier$16,805,433
- Laurent Gapin$8,662,236
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteTnfrsf5 GeneDiabetes MellitusCellsTnfsf5 GeneDesignPreventGrantInsulin-Dependent Diabetes MellitusAutoimmune ProcessInbred Nod MiceHyperglycemiaMediatingAutoimmune DiseasesAffectPlayHaplotypesSpecificityPeptidesPathogenicityInsulinReceptorInflammatoryMonoclonal Antibodies
Grant awards (21)
Discovering the Mechanism of Action of a peptide drug, OPT101, that targets CD40 mediated inflammation in type 1 diabetes$396,060
R01 · FY2025 · DK · contact PI
Discovering the Mechanism of Action of a peptide drug, OPT101, that targets CD40 mediated inflammation in type 1 diabetes$422,463
R01 · FY2024 · DK · contact PI
Discovering the Mechanism of Action of a peptide drug, OPT101, that targets CD40 mediated inflammation in type 1 diabetes$440,065
R01 · FY2023 · DK · contact PI
Discovering the Mechanism of Action of a peptide drug, OPT101, that targets CD40 mediated inflammation in type 1 diabetes$440,065
R01 · FY2022 · DK · contact PI
Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes$764,501
R42 · FY2020 · AI · contact PI
Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes$1,000,000
R42 · FY2019 · AI · contact PI
Development of a Clinical Screening Platform for Type 1 Diabetes$594,177
R42 · FY2019 · DK · contact PI
Development of a Clinical Screening Platform for Type 1 Diabetes$561,109
R42 · FY2018 · DK · contact PI
Development of a Clinical Screening Platform for Type 1 Diabetes$421,182
R42 · FY2017 · DK · contact PI
Screening for the autoimmune component of multiple sclerosis$299,002
R41 · FY2017 · AI · contact PI
Developing a small peptide to control autoimmune inflammation in type 1 diabetes$297,387
R41 · FY2017 · AI · contact PI
A unique approach to control the CD40/CD154 inflammatory axis in type 1 diabetes$232,563
R21 · FY2014 · AI · contact PI
Developing a new treatment for MS: Controlling CD40 in EAE$211,808
R41 · FY2014 · AI · contact PI
A unique approach to control the CD40/CD154 inflammatory axis in type 1 diabetes$181,587
R21 · FY2013 · AI · contact PI
CD40-Induced TCR Revision: A Mechanism for Autoimmunity$272,906
R01 · FY2011 · DK · contact PI
CD40-Induced TCR Revision: A Mechanism for Autoimmunity$275,663
R01 · FY2010 · DK · contact PI
CD40-Induced TCR Revision: A Mechanism for Autoimmunity$154,586
R01 · FY2010 · DK · contact PI
CD40-Induced TCR Revision: A Mechanism for Autoimmunity$278,447
R01 · FY2009 · DK · contact PI
CD40-Induced TCR Revision: A Mechanism for Autoimmunity$1,540
R01 · FY2009 · DK · contact PI
CD40-Induced TCR Revision: A Mechanism for Autoimmunity$278,447
R01 · FY2008 · DK · contact PI
CD40-Induced TCR Revision: A Mechanism for Autoimmunity$284,130
R01 · FY2007 · DK · contact PI